Whittier Trust Co. of Nevada Inc. Buys 2,432 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Whittier Trust Co. of Nevada Inc. lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,614 shares of the medical research company’s stock after acquiring an additional 2,432 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in IQVIA were worth $10,142,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Private Trust Co. NA grew its stake in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares during the period. Pine Valley Investments Ltd Liability Co grew its stake in IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 50 shares during the period. Howard Capital Management Inc. grew its stake in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after purchasing an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after purchasing an additional 56 shares during the period. Finally, Cypress Wealth Services LLC grew its stake in IQVIA by 4.8% in the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 57 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $184.13 on Friday. The business’s 50-day moving average price is $195.30 and its two-hundred day moving average price is $209.18. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $256.29. The stock has a market cap of $32.46 billion, a P/E ratio of 24.55, a PEG ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Truist Financial restated a “buy” rating and issued a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. UBS Group dropped their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, Bank of America dropped their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.